102 related articles for article (PubMed ID: 24694672)
1. Hormone therapy for patients with advanced or recurrent endometrial cancer.
Lee WL; Yen MS; Chao KC; Yuan CC; Ng HT; Chao HT; Lee FK; Wang PH
J Chin Med Assoc; 2014 May; 77(5):221-6. PubMed ID: 24694672
[TBL] [Abstract][Full Text] [Related]
2. Hormonal therapy in advanced or recurrent endometrial cancer.
Kokka F; Brockbank E; Oram D; Gallagher C; Bryant A
Cochrane Database Syst Rev; 2010 Dec; 2010(12):CD007926. PubMed ID: 21154390
[TBL] [Abstract][Full Text] [Related]
3. Questions remain on progestin effectiveness for advanced and recurrent endometrial cancer.
Qi Y; Zhang J
BJOG; 2024 Feb; 131(3):381-382. PubMed ID: 37366024
[No Abstract] [Full Text] [Related]
4. Promising novel therapies for the treatment of endometrial cancer.
Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2010 Feb; 116(2):187-94. PubMed ID: 19903572
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and therapeutic challenges in a recurrent endometrial carcinoma in lung, 15 years after primary treatment.
Upadhyay AK; Kumar M; Prakash A; Kumar A
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38782427
[TBL] [Abstract][Full Text] [Related]
6. [Dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer].
Raynaud C; Rodrigues M
Bull Cancer; 2024 May; 111(5):433-434. PubMed ID: 38493028
[No Abstract] [Full Text] [Related]
7. The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma.
Ray-Coquard I; Monk BJ; Lorusso D; Mahdi H; Upadhyay V; Graul R; Husain A; Mirza MR; Slomovitz B
Int J Gynecol Cancer; 2023 Dec; 33(12):1943-1949. PubMed ID: 37907262
[TBL] [Abstract][Full Text] [Related]
8. Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens.
Richardson M; Chase DM
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):1-8. PubMed ID: 37792525
[TBL] [Abstract][Full Text] [Related]
9. Endometrial adenocarcinoma in a 27-year-old woman.
Fadhlaoui A; Ben Hassouna J; Khrouf M; Zhioua F; Chaker A
Clin Med Insights Case Rep; 2010; 3():31-9. PubMed ID: 21769252
[TBL] [Abstract][Full Text] [Related]
10. Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer.
Chan JK; Tewari K; Monk BJ; Herzog TJ; Coleman RL; Richardson MT; Kapp DS; Francoeur AA
Gynecol Oncol; 2024 Jun; 187():249-252. PubMed ID: 38838439
[No Abstract] [Full Text] [Related]
11. Two pathogenetic types of endometrial carcinoma.
Bokhman JV
Gynecol Oncol; 1983 Feb; 15(1):10-7. PubMed ID: 6822361
[TBL] [Abstract][Full Text] [Related]
12. EXOSC5 maintains cancer stem cell activity in endometrial cancer by regulating the NTN4/integrin β1 signalling axis.
Huang YH; Wang WL; Wang PH; Lee HT; Chang WW
Int J Biol Sci; 2024; 20(1):265-279. PubMed ID: 38164180
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Metastasis of Endometrial Cancer and Long-Term Survival: A Scoping Review and Our Experience.
Nienhaus A; Rajakulendran R; Bernad E
Diagnostics (Basel); 2023 Aug; 13(15):. PubMed ID: 37568966
[TBL] [Abstract][Full Text] [Related]
14. Invasiveness of endometrial cancer cell lines is potentiated by estradiol and blocked by a traditional medicine Guizhi Fuling at clinically relevant doses.
Khan S; Varricchio A; Ricciardelli C; Yool AJ
Front Oncol; 2022; 12():1015708. PubMed ID: 36727068
[TBL] [Abstract][Full Text] [Related]
15. The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis.
van Weelden WJ; Birkendahl PB; Lalisang RI; IntHout J; Kruitwagen RFPM; Romano A; Pijnenborg JMA
BJOG; 2023 Jan; 130(2):143-152. PubMed ID: 36264251
[TBL] [Abstract][Full Text] [Related]
16. TRIMming Down Hormone-Driven Cancers: The Biological Impact of TRIM Proteins on Tumor Development, Progression and Prognostication.
Pauletto E; Eickhoff N; Padrão NA; Blattner C; Zwart W
Cells; 2021 Jun; 10(6):. PubMed ID: 34208621
[TBL] [Abstract][Full Text] [Related]
17. Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer.
Wang C; Tran DA; Fu MZ; Chen W; Fu SW; Li X
J Cancer; 2020; 11(7):1693-1701. PubMed ID: 32194781
[No Abstract] [Full Text] [Related]
18. Pathogenesis and Clinical Management of Uterine Serous Carcinoma.
Zhang L; Kwan SY; Wong KK; Solaman PT; Lu KH; Mok SC
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183290
[TBL] [Abstract][Full Text] [Related]
19. The Identification and Analysis of mRNA-lncRNA-miRNA Cliques From the Integrative Network of Ovarian Cancer.
Zhou Y; Zheng X; Xu B; Hu W; Huang T; Jiang J
Front Genet; 2019; 10():751. PubMed ID: 31497032
[TBL] [Abstract][Full Text] [Related]
20. Curcumin and endometrial carcinoma: an old spice as a novel agent.
El Khoury D; Matar R; Touma T
Int J Womens Health; 2019; 11():249-256. PubMed ID: 31354362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
